Rapamycin + Exercise Trial: What RAPA-EX-01 Actually Showed (2026)

A Negative Result That Should Reset the Conversation

For nearly a decade, rapamycin has held an outsized place in longevity discourse — largely driven by promising mouse data, online physician influencers, and well-funded biohacker communities. The first randomized, double-blind, placebo-controlled trial pairing rapamycin with structured exercise in older adults has now been published, and the result is unambiguous: the drug did not enhance the benefits of training. In several measures, it appeared to attenuate them. Adverse events also clustered on the rapamycin arm.

The Trial: RAPA-EX-01

The study, published in the Journal of Cachexia, Sarcopenia and Muscle in March 2026, enrolled previously sedentary older adults and randomized them to one of two arms: weekly 6 mg sirolimus (the generic name for rapamycin) plus a structured combined resistance and endurance training program, or matched placebo plus the same training. Both groups exercised under supervision for 13 weeks. Investigators measured strength, endurance, body composition, and a battery of functional outcomes including the short physical performance battery and grip strength.

The protocol was designed to give rapamycin its best chance. Participants were screened to exclude diabetes and immunosuppressive comorbidities. The exercise stimulus was substantial — not a token walking program, but a real combined load that drove measurable adaptation in the placebo group. The dosing schedule (6 mg once weekly) was the regimen most commonly recommended by online clinicians, including the one popularized in podcasts and longevity newsletters.

If rapamycin had a real, additive effect on top of exercise in older adults, this trial was structured to detect it.

What the Data Showed

The placebo group, predictably, gained strength and functional capacity over 13 weeks. Exercise works. The rapamycin group did not gain more — and several markers trended in the wrong direction. The investigators describe an apparent attenuation of training adaptations on the active arm, although the trial was not powered to confirm this with statistical certainty.

The adverse event profile was also worse on rapamycin. Mouth ulcers, lipid abnormalities, and lower-grade gastrointestinal symptoms accumulated more frequently in the active arm. None of this is novel — these have been the classic dose-limiting effects of sirolimus in transplant medicine for decades — but it is the first time they have been documented in healthy, sedentary older adults using the doses popular in longevity circles.

Lead author Brad Stanfield, a New Zealand general practitioner, summarized the takeaway in plain language: “Exercise remains the single best intervention for preserving function in older adults. Full stop.”

Why This Trial Carries Unusual Weight

Trials of off-label longevity interventions are often funded by the supplement industry, by biotech companies with skin in the game, or by foundations whose donors hold strong priors. RAPA-EX-01 was funded differently. Stanfield is a clinician and educator whose YouTube channel funded much of the work directly through his personal company, Dr Brad Stanfield Ltd. The remainder came from VitaDAO, a public crowdfund that raised money explicitly to test longevity hypotheses without industry strings attached.

This matters. A negative result from an industry-sponsored trial is easy to dismiss as a one-off. A negative result from an independently funded, publicly accountable trial is harder to wave away. The investigators had no commercial reason to bury inconvenient findings.

The co-investigator slate adds further credibility. Matt Kaeberlein, who joined the study, is one of the most cited researchers in the mTOR field globally. He is not a rapamycin skeptic by background — his career has been spent characterizing the pathway that rapamycin inhibits. When Kaeberlein co-signs a trial that fails to find benefit in healthy older adults, that signal carries information.

The Counter-Argument: One Trial Is Not Enough

Not everyone has accepted the result at face value. Peter Attia, the physician whose podcast and clinic have been central to rapamycin’s popularization, has argued that a single 13-week study is insufficient to overturn the prior literature. The argument deserves a fair hearing. Mouse data on rapamycin and lifespan extension is one of the most replicated results in geroscience. The dose, duration, and outcome measures of any single human trial are necessarily a single point in a much larger possible design space. Larger and longer trials may yet show benefit on outcomes RAPA-EX-01 was not designed to measure — cognitive aging, immune function, or biomarker trajectories over years rather than weeks.

This is a legitimate scientific position. It is also the same argument that has been deployed for years to defer the harder question: what evidence would change your mind? RAPA-EX-01 was the trial many in the longevity community said they wanted. It was independently funded. It used the dose protocol most commonly recommended. It paired rapamycin with the intervention everyone agrees works (exercise) so the drug had a real chance to add incremental value. The result is what it is.

The reasonable response is not “this changes nothing” — but it is also not “rapamycin is now disproven.” It is closer to: anyone still recommending weekly rapamycin to healthy older adults now bears a substantially heavier burden of evidence than they did a year ago.

What Healthspan Readers Should Take From This

The readership of this site does not need another pharmacological adventure. Most of the highest-leverage interventions for preserving function with age remain unprescribed and unpatentable. They are: resistance training twice or three times per week, adequate protein intake, sleep hygiene, cardiovascular exercise that raises heart rate, and a diet built around minimally processed foods. Every one of these has more supporting evidence than rapamycin has accumulated in healthy adults across the past two decades combined.

If you are already exercising and eating well, the marginal benefit of adding a weekly immunosuppressant — with documented side effects, no demonstrated upside in this population, and a regulatory category that means your doctor will not prescribe it for this purpose — is now less defensible than it was. There may be subgroups for whom rapamycin eventually proves useful. Established sarcopenia, specific metabolic phenotypes, or post-cancer immune contexts are all plausible. None of them describe the typical reader of this site.

The Process Matters as Much as the Result

The most encouraging part of RAPA-EX-01 is not the result itself — it is the existence of the trial. The longevity field has been criticized, fairly, for over-relying on mouse studies and physician anecdote. A clinician-funded, crowdfunded, peer-reviewed RCT in the relevant population is exactly the kind of evidence the field needs more of. The fact that it produced a negative result strengthens its credibility, not weakens it. Researchers who only publish positive findings have a disclosure problem; researchers who publish what they find regardless of the result have a credibility surplus.

Expect more trials like this one. VitaDAO and similar public funding mechanisms have several other geroscience candidates in their pipeline. Some will produce positive results. Others will not. That is what evidence looks like when no one is paying for a particular conclusion.

Sources:
Stanfield B, Leroux B, Kaeberlein M, Jones J, Lucas R. Exercise and weekly sirolimus (rapamycin) in older adults: RAPA-EX-01 randomised, double-blind, placebo-controlled trial. J Cachexia Sarcopenia Muscle. 2026;17(2):e70274.